Australia's Incannex rises on positive data from study on sleep apnoea drug
03/06/2022 02:08
** ASX-listed shares of cannabinoid pharmaceutical firm
Incannex Healthcare IHL.AX rise as much as 13.3% to A$0.425,
their best intraday session since May 13
** Says a data from a mid-stage proof-of-concept clinical
trial for its obstructive sleep apnoea drug showed patients saw
improved sleep quality, and the drug was well tolerated
urn:newsml:reuters.com:*:nASX1z4tvh
** Adds that it has completed a meeting with U.S. FDA before
the investigative new drug application (IND), and the next step
will be the IND opening clinical trial
** IHL down 40% YTD, as of last close
(Reporting by Harshita Swaminathan)
((Harshita.Swaminathan@thomsonreuters.com))
Recent news on Incannex Healthcare
See all newsBrief: Incannex Healthcare Says Computershare To Be Appointed As US Transfer Agent
Brief: Incannex Healthcare Says Federal Court Of Australia Approved Proposed Schemes Of Arrangement Between Incannex And Its Shareholders
Australia's Incannex up as shareholders in favour of US redomicile
Brief: Incannex Healthcare Will Prepare FDA Ind Application PSI-Gad
Brief: Review Of Ind Application For Ihl-42X By Us FDA Has Been Completed Clinical Trial For Patients With Obstructive Sleep Apnoea May Proceed